These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21206986)

  • 1. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
    De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
    Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
    Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
    Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors.
    Lima LM; de Souza LR; da Silva TF; Pereira CS; Guimarães AL; de Paula AM; de Andrade Carvalho H
    Histopathology; 2012 Feb; 60(3):489-96. PubMed ID: 22176134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
    Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
    N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
    Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
    Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
    Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
    Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
    Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
    Gao Y; Liu D
    Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
    Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
    J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
    Bai ZL; Wang YY; Zhe H; He JL; Hai P
    Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.
    Pectasides E; Rampias T; Kountourakis P; Sasaki C; Kowalski D; Fountzilas G; Zaramboukas T; Rimm D; Burtness B; Psyrri A
    Clin Cancer Res; 2011 May; 17(9):2947-54. PubMed ID: 21355076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.
    Bišof V; Jakovčević A; Seiwerth S; Rakušić Z; Gašparov S
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):187-94. PubMed ID: 23011763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
    Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
    Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.